Streetbeat News

ENLV

Enlivex Therapeutics Ltd.

https://www.enlivex.com

Industry

Biotechnology

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.

Open

1.22

Mkt cap

26M

Volume

123K

High

1.23

P/E Ratio

-1.22

52-wk high

4.59

Low

1.15

Div yield

N/A

52-wk low

0.81

Enlivex Therapeutics Ltd. has received regulatory authorization from the Israeli Ministry of Health to begin a Phase I trial for Allocetra in patients with TMJ osteoarthritis.

Portfolio Pulse from

December 11, 2024 | 1:45 pm

Enlivex Therapeutics Ltd. announced positive interim efficacy data from its Phase I/II Allocetra trial for knee osteoarthritis, potentially boosting investor confidence.

Portfolio Pulse from

December 05, 2024 | 4:00 pm

Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, is hosting a live investor webinar and Q&A session on December 3, 2024. This event aims to engage investors and provide updates on the company's progress.

Portfolio Pulse from

November 26, 2024 | 3:30 pm

Enlivex Therapeutics Ltd. has dosed the first patient in a Phase I clinical trial for Allocetra, targeting psoriatic arthritis. Initial results show no safety concerns.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

Enlivex has received a Notice of Allowance for its Japanese patent application for the use of Allocetra in treating osteoarthritis. The patent is expected to be formally issued in Japan by the end of Q2 2025.